Loading...
Kodiak Sciences Q4 2024 Earnings Report
Kodiak Sciences reported its business highlights and financial results for the fourth quarter and full year ended December 31, 2024.
Key Takeaways
Kodiak Sciences reported a net loss of $44.1 million for Q4 2024, an improvement from $59.5 million in Q4 2023. The company's cash and cash equivalents stood at $168.1 million, which is expected to support operations into 2026. Research and development expenses decreased significantly, driven by reduced manufacturing activities and equity award forfeitures.
Net loss for Q4 2024 was $44.1 million, an improvement from $59.5 million in Q4 2023.
Research and development expenses decreased to $31.8 million in Q4 2024 from $46.6 million in Q4 2023.
General and administrative expenses decreased to $14.4 million in Q4 2024 from $16.7 million in Q4 2023.
Cash and cash equivalents were $168.1 million at the end of Q4 2024, expected to fund operations into 2026.
Kodiak Sciences
Kodiak Sciences
Forward Guidance
Kodiak Sciences anticipates significant progress in its clinical trials for tarcocimab, KSI-501, and KSI-101, with key data readouts and regulatory milestones expected in 2026. The company also plans to advance its VETi program and pipeline of investigational therapies for retinal diseases.
Positive Outlook
- GLOW2 and DAYBREAK Phase 3 studies for tarcocimab are on track for topline data announcements in 1Q 2026 and 2Q 2026, respectively, aiming for a single BLA filing in 2026.
- KSI-501 is being explored in the DAYBREAK study for differentiated efficacy against aflibercept, with regulatory pathway considerations for broad indications.
- KSI-101 initiated its APEX Phase 1b clinical study in 1H 2024, with plans to share data supporting its potential as a cornerstone therapy for macular edema inflammation in June 2025 and initiate pivotal study in 2Q 2025.
- Advancement of the ABC® platform for investigational therapies addressing ocular durability and multi-functional mechanisms of action for glaucoma and geographic atrophy.
- Continued progress of the VETi program, aiming for commercialization with retinal medicines and potential for broader human disease correlations.
Challenges Ahead
- Risk that cessation or delay of ongoing clinical studies for tarcocimab, KSI-501, or KSI-101 may occur.
- Risk that results of clinical studies may not provide anticipated evidence, insights, or benefits.
- Risk that safety, efficacy, and durability data observed in current or prior studies may not continue or persist.
- Risk that Phase 3 study results may be insufficient to support a single BLA submission or that BLA may not be accepted or approved by regulatory agencies.
- Risk that research and development efforts or ability to advance product candidates into later stages may fail, or that product candidates may not be successfully developed, approved, or commercialized.